Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;16(7):873-880.
doi: 10.1177/1747493020978345. Epub 2020 Dec 9.

The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods

S Iris Deeds  1 , Andrew Barreto  2 , Jordan Elm  3 , Colin P Derdeyn  4 , Scott Berry  5 , Pooja Khatri  6 , Claudia Moy  7 , Scott Janis  7 , Joseph Broderick  6   8 , James Grotta  9 , Opeolu Adeoye  1
Affiliations

The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods

S Iris Deeds et al. Int J Stroke. 2021 Oct.

Abstract

Background: Intravenous recombinant tissue plasminogen activator is the only proven effective medication for the treatment of acute ischemic stroke. Two approaches that may augment recombinant tissue plasminogen activator thrombolysis and prevent arterial reocclusion are direct thrombin inhibition with argatroban and inhibition of the glycoprotein 2b/3a receptor with eptifibatide.

Aim: The multi-arm optimization of stroke thrombolysis trial aims to determine the safety and efficacy of intravenous therapy with argatroban or eptifibatide as compared with placebo in acute ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator within 3 h of symptom onset.

Sample size estimate: A maximum of 1200 randomized subjects to test the superiority of argatroban or eptifibatide to placebo in improving 90-day modified Rankin scores.

Methods and design: Multiarm optimization of stroke thrombolysis is a multicenter, multiarm, adaptive, single blind, randomized controlled phase 3 clinical trial conducted within the National Institutes of Health StrokeNet clinical trial network. Patients treated with 0.9 mg/kg intravenous recombinant tissue plasminogen activator within 3 h of stroke symptom onset are randomized to receive intravenous argatroban (100 µg/kg bolus followed by 3 µg/kg/min for 12 h), intravenous eptifibatide (135 µg/kg bolus followed by 0.75 µg/kg/min infusion for 2 h) or IV placebo. Patients may receive endovascular thrombectomy per usual care.

Study outcomes: The primary efficacy outcome is improved modified Rankin score assessed at 90 days post-randomization.

Discussion: Multiarm optimization of stroke thrombolysis is an innovative and collaborative project that is the culmination of many years of dedicated efforts to improve outcomes for stroke patients.

Trial registration: ClinicalTrials.gov NCT03735979.

Keywords: Acute ischemic stroke; alteplase recombinant tissue plasminogen activator; argatroban; clinical trial; eptifibatide; recanalization; recombinant tissue plasminogen activator.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Colin P Derdeyn: Consultant – Penumbra (DSMB, MIND trial); Nono (DSMB, ESCAPE NA1 trial); Genae (DSMB Tigertriever trial); Equity – Pulse Therapeutics (Scientific Advisory Board, Stock Options). Joseph Broderick: Department of Neurology and Rehabilitation Medicine receives monies from Genentech Inc. for his role on Executive Committee of TIMELESS Trial. Opeolu Adeoye: Founder and Equity Holder, Sense Diagnostics, Inc.

Figures

Figure 1.
Figure 1.
Protocol for aPTT titration.
Figure 2.
Figure 2.
Schematic of study treatment administration.
See this image and copyright information in PMC

References

    1. Adeoye O, Barreto A, Broderick J, Derdeyn C and Grotta J. MOST stroke trial protocol, https://nihstrokenet.org/most/resources (accessed 9 March 2020).
    1. Alexandrov AV and Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59: 862–867. - PubMed
    1. Rubiera M, Alvarez-Sabin J, Ribo M, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke 2005; 36: 1452–1456. - PubMed
    1. Rha JH and Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007; 38: 967–973. - PubMed
    1. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS and del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt- PA Acute Stroke Study Group. Am J Neroradiol 1993; 14: 3–13. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data